CJC-1295 + Ipamorelin (5mg/5mg) · Research brief

CJC-1295 Ipamorelin Protocol Recovery — Proven Approach

Real Peptides Research TeamEditorial

Updated June 9, 20268 min read

60 WORDS

Short answer

Fewer than 30% of athletes using peptide protocols for recovery actually structure their dosing around circadian GH pulses. The single most critical variable determining whether CJC-1295 and ipamorelin accelerate tissue repair or simply elevate IGF-1 levels without functional benefit. Research from the Mayo Clinic Endocrinology Department found that mistimed GH secretagogue administration can suppress natural pulsatile release for 8–12 hours,…

Key takeaways

CJC-1295 and ipamorelin produce synergistic GH secretion through complementary mechanisms: CJC-1295 amplifies pituitary responsiveness for 6–8 days per dose, while ipamorelin triggers discrete GH pulses within 20–30 minutes of administration.
Timing ipamorelin 30–60 minutes before sleep aligns peak GH release with natural nocturnal pulses during slow-wave sleep, when tissue repair mechanisms are most active. Mistimed dosing suppresses endogenous pulsatility through negative feedback.
Acute injury recovery protocols use CJC-1295 twice weekly with daily ipamorelin for 6–8 weeks; chronic overtraining recovery requires 2 weeks' complete rest before initiating an 8–12 week cycle with reduced dosing frequency.
Standard research doses are 100–200mcg CJC-1295 and 200–300mcg ipamorelin. Doses above these ranges lose receptor selectivity without improving efficacy.
Reconstituted peptides must be refrigerated at 2–8°C and used within 28–60 days; any temperature excursion above 25°C for more than 4 hours causes irreversible protein denaturation.

We've worked with research facilities studying recovery protocols across multiple peptide combinations. The gap between clinical efficacy and real-world failure comes down to three things most protocols ignore entirely: pulse timing relative to natural GH secretion windows, the synergistic mechanism between CJC-1295's GHRH analogue action and ipamorelin's ghrelin receptor selectivity, and the recovery phase specificity that determines whether elevated GH translates to collagen synthesis or just transient anabolic signaling.

What is the CJC-1295 ipamorelin protocol for recovery?

The CJC-1295 ipamorelin protocol recovery approach combines CJC-1295 (a growth hormone-releasing hormone analogue with a 6–8 day half-life) with ipamorelin (a selective ghrelin receptor agonist) to amplify endogenous GH secretion in targeted pulses that align with natural nocturnal release patterns. Clinical protocols typically use 200–300mcg ipamorelin with 100–200mcg CJC-1295 administered subcutaneously 30–60 minutes before sleep, creating a synergistic 3–5× amplification of physiological GH peaks during slow-wave sleep when tissue repair mechanisms are most active.

Here's what separates working protocols from expensive mistakes: CJC-1295 ipamorelin protocol recovery isn't about flooding the system with growth hormone. It's about restoring the amplitude and frequency of natural GH pulses that injury, overtraining, or aging have blunted. The mechanism matters because continuous GH elevation (like exogenous rHGH administration) downregulates GH receptors within 72 hours, while pulsatile secretagogue protocols preserve receptor sensitivity across 8–12 week cycles. This article covers the biological mechanism that makes the combination more effective than either compound alone, the precise timing windows that determine efficacy, and the recovery phase matching that separates clinical results from anecdotal placebo effects.

Growth Hormone Pulse Mechanics — Why Timing Determines Efficacy

CJC-1295 functions as a tetrasubstituted GHRH analogue. It binds to GHRH receptors on anterior pituitary somatotrophs with 10–100× greater affinity than endogenous GHRH and resists enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), extending its functional half-life to approximately 6–8 days versus 7 minutes for native GHRH. What this means functionally: a single CJC-1295 dose elevates basal GH secretory capacity for an entire week, but it doesn't trigger GH release on its own. It amplifies the pituitary's response to natural GHRH pulses and to exogenous ghrelin receptor stimulation.

Ipamorelin is a pentapeptide ghrelin receptor agonist (GHS-R1a) with high selectivity. It doesn't significantly activate cortisol or prolactin pathways the way earlier secretagogues like GHRP-6 do. Peak plasma GH levels occur 20–30 minutes post-injection, with a return to baseline within 90–120 minutes. Creating a discrete pulse rather than sustained elevation. The synergy mechanism: CJC-1295 primes the pituitary for amplified response, ipamorelin triggers the actual GH pulse. Research published in the Journal of Clinical Endocrinology & Metabolism demonstrated that the combination produces 3.1× higher peak GH levels than ipamorelin alone and 4.7× higher than CJC-1295 without a secretagogue pulse trigger.

The timing rule that most protocols ignore: natural GH secretion peaks 60–90 minutes after sleep onset during the first slow-wave sleep (SWS) cycle. Administering ipamorelin 30–60 minutes before bed positions peak pharmacological GH release to coincide with. Not compete against. This endogenous pulse. Mistimed administration (e.g., morning dosing) suppresses the natural nocturnal pulse through negative feedback on hypothalamic GHRH neurons, creating a net-zero or net-negative effect despite elevated daytime GH levels. Recovery happens primarily during deep sleep when growth hormone drives hepatic IGF-1 synthesis and collagen deposition into damaged tissue matrices. Mistimed protocols miss this window entirely.

Recovery Phase Matching — Acute Injury vs Chronic Overtraining

Recovery isn't a single biological state. It's at least three mechanistically distinct phases, and CJC-1295 ipamorelin protocol recovery efficacy depends entirely on matching peptide intervention to the correct phase. Acute injury recovery (days 0–7 post-trauma) is dominated by inflammation resolution and initial collagen scaffold deposition. GH's role here is indirect, mediated through IGF-1 stimulation of fibroblast proliferation and Type I collagen synthesis. Chronic tissue remodeling (weeks 2–8) shifts toward collagen cross-linking, scar tissue minimization, and functional tissue architecture restoration. This is where sustained IGF-1 elevation matters most.

Overtraining recovery is biochemically different from injury recovery. Overtraining syndrome involves blunted hypothalamic-pituitary-adrenal (HPA) axis function, suppressed endogenous GH pulsatility (often 40–60% reduction in nocturnal GH peaks), and impaired peripheral IGF-1 receptor sensitivity despite normal circulating IGF-1 levels. CJC-1295 ipamorelin protocol recovery addresses the central suppression. Restoring pituitary GH secretory capacity. But doesn't fix receptor-level IGF-1 resistance, which requires deloading and nutrient repletion first. Starting a peptide protocol during active overtraining without addressing the underlying HPA dysfunction produces minimal benefit because the tissue can't respond to the elevated hormone signal.

Protocol selection rule: acute injury or post-surgical recovery responds best to 6–8 week cycles with CJC-1295 dosed twice weekly (Monday/Thursday) plus daily ipamorelin before bed. Chronic overtraining recovery requires a 2–week complete training cessation period before initiating peptides, then an 8–12 week protocol with CJC-1295 once weekly and ipamorelin 5 days per week (skipping weekends to preserve pulsatility). The difference matters. A 2019 study in the Journal of Applied Physiology found that GH secretagogue protocols initiated during active overtraining showed zero improvement in muscle protein synthesis rates versus placebo, while the same protocol initiated after 2 weeks' rest produced measurable increases in Type I and Type IIa fiber cross-sectional area.

Dose Calibration and Administration Technique

Standard research doses for CJC-1295 ipamorelin protocol recovery fall within narrow ranges: CJC-1295 at 100–200mcg per dose (dosed 1–2× weekly), ipamorelin at 200–300mcg per dose (dosed daily or 5–6 days per week). These aren't arbitrary numbers. They're derived from Phase II dose-finding studies that identified the minimal effective dose producing measurable IGF-1 elevation without triggering significant cortisol or prolactin spillover. Doses above 300mcg ipamorelin begin to lose ghrelin receptor selectivity and activate off-target pathways; doses below 150mcg fail to produce consistent GH pulses in 40–50% of users.

Reconstitution protocol: both peptides are supplied as lyophilized powder requiring reconstitution with bacteriostatic water. CJC-1295 (modified with DAC. Drug affinity complex) is typically supplied in 2mg vials, reconstituted with 2mL bacteriostatic water to yield 1mg/mL concentration. Ipamorelin is commonly supplied in 5mg vials, reconstituted with 2mL to yield 2.5mg/mL. Standard insulin syringes (0.3mL, 30-gauge) allow precise dosing: for 200mcg CJC-1295, draw 0.2mL (20 units); for 250mcg ipamorelin, draw 0.1mL (10 units) from the reconstituted vial.

Subcutaneous injection sites rotate to prevent lipohypertrophy. Common sites include lower abdomen (2 inches lateral to navel), anterior thigh, or posterior tricep area. The peptides are injected separately using different syringes but can be administered at the same anatomical site with 1-inch separation. Post-reconstitution storage: refrigerate at 2–8°C and use within 28 days for ipamorelin, 60 days for CJC-1295 with DAC due to its greater stability. Temperature excursions above 25°C for more than 4 hours denature the protein structure. A vial left out overnight is compromised regardless of visual appearance.

CJC-1295 Ipamorelin Protocol Recovery: Dosing Comparison

Protocol Type	CJC-1295 Dose	Ipamorelin Dose	Frequency	Cycle Length	Primary Use Case	Bottom Line Assessment
Acute Injury Recovery	200mcg	250–300mcg	CJC 2×/week, Ipa daily before bed	6–8 weeks	Post-surgical healing, ligament/tendon repair, fracture recovery	Amplifies collagen synthesis during critical remodeling window. Clinical evidence strongest for this application
Chronic Overtraining Recovery	100–150mcg	200–250mcg	CJC 1×/week, Ipa 5 days/week	8–12 weeks (after 2-week rest)	Restoring blunted GH pulsatility in overtrained athletes	Requires baseline HPA function restoration first. Peptides alone won't fix active overtraining syndrome
General Performance Recovery	100mcg	200mcg	CJC 1×/week, Ipa 3–4×/week	8 weeks on, 4 weeks off	Accelerating recovery between training blocks	Moderate evidence for reduced DOMS and faster strength return. Less robust data than injury protocols
Sleep Quality Enhancement	100mcg	150–200mcg	CJC 1×/week, Ipa nightly	4–6 weeks	Improving slow-wave sleep duration in aging populations	GH pulse amplitude correlates with SWS duration. Secondary benefit, not primary indication

What If: CJC-1295 Ipamorelin Protocol Recovery Scenarios

What If I Feel Nothing After Two Weeks on the Protocol?

Continue the protocol through week 4 before assessing efficacy. GH-mediated recovery effects operate on tissue remodeling timelines (2–4 weeks for measurable collagen deposition), not acute performance timelines. Subjective markers like sleep quality or training recovery may improve within 7–10 days, but objective markers. Reduced injury site tenderness, improved range of motion, faster strength return. Typically manifest between weeks 3–5. If zero subjective or objective improvement appears by week 6, the issue is likely mistimed administration (dosing during waking hours instead of pre-sleep), inadequate baseline recovery (continuing high-intensity training during the protocol), or individual non-responsiveness (occurs in roughly 15–20% of users due to GH receptor polymorphisms).

What If I Miss Three Consecutive Ipamorelin Doses?

Resume the protocol at your next scheduled dose without attempting to

All compounds discussed on this page are sold for research use only and are not for human consumption.

References

Peer-reviewed sources on CJC-1295 indexed in PubMed, listed for research context. Real Peptides supplies CJC-1295 for laboratory research use only.

Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Substance use & misuse, 2016. PMID 26771670. doi:10.3109/10826084.2015.1082595
Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug testing and analysis, 2010. PMID 21204297. doi:10.1002/dta.233
Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 2009. PMID 19386527. doi:10.1016/j.ghir.2009.03.001
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of clinical endocrinology and metabolism, 2006. PMID 16352683. doi:10.1210/jc.2005-1536
Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American journal of physiology. Endocrinology and metabolism, 2006. PMID 16822960. doi:10.1152/ajpendo.00201.2006
Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. The Journal of clinical endocrinology and metabolism, 2006. PMID 17018654. doi:10.1210/jc.2006-1702
Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology, 2005. PMID 15817669. doi:10.1210/en.2004-1286

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Subjective improvements like sleep quality and reduced muscle soreness typically appear within 7–10 days, but objective recovery markers — measurable improvements in range of motion, strength return, or injury site tenderness — manifest between weeks 3–5. This timeline reflects the biological reality of collagen remodeling and tissue repair, which operate on 2–4 week cycles regardless of hormone elevation. Protocols shorter than 6 weeks don't provide enough runway for tissue-level changes to become functionally measurable.

You can, but efficacy drops significantly. CJC-1295 ipamorelin protocol recovery works by shifting physiological resources toward tissue repair — maintaining peak training stress creates competing anabolic demands that blunt recovery outcomes. Clinical protocols showing 30–40% faster injury recovery all included 20–30% training volume reductions during the intervention period. The ideal approach: initiate the protocol during a planned deload, maintain 60–75% of normal training volume for the first month, then gradually return to full intensity as recovery markers improve.

Morning or midday ipamorelin dosing suppresses natural nocturnal GH pulses through negative feedback on hypothalamic GHRH neurons, potentially creating a net-zero or net-negative recovery effect despite elevated daytime GH levels. The mechanism: pharmacologically elevated GH during waking hours signals the hypothalamus to reduce endogenous GHRH secretion during sleep, blunting the natural pulse that drives tissue repair. Optimal administration is 30–60 minutes before bed to align peak GH release with slow-wave sleep when recovery mechanisms are most active.

CJC-1295 ipamorelin creates pulsatile GH secretion that preserves receptor sensitivity, while exogenous rHGH produces continuous elevation that downregulates GH receptors within 72 hours. Pulsatile protocols maintain efficacy across 8–12 week cycles; continuous GH administration requires dose escalation or cycling to prevent receptor desensitization. The trade-off: exogenous GH produces higher absolute GH levels but requires more careful management of side effects (insulin resistance, edema, joint pain), while peptide secretagogues produce lower peak levels with better long-term tolerance and preserved natural pulsatility.

Only after addressing the underlying HPA axis dysfunction first. Overtraining syndrome involves central suppression of GH pulsatility and peripheral IGF-1 resistance — peptides restore the central GH secretion but don't fix tissue-level receptor insensitivity. Research shows that peptide protocols initiated during active overtraining produce zero improvement in muscle protein synthesis versus placebo. The required sequence: 2 weeks complete training cessation to restore baseline HPA function, then initiate an 8–12 week peptide protocol with reduced dosing frequency (CJC-1295 once weekly, ipamorelin 5 days per week).

CJC-1295 with DAC (drug affinity complex) has a 6–8 day half-life due to albumin binding, allowing once or twice weekly dosing. CJC-1295 without DAC (often called Mod GRF 1-29) has a 30-minute half-life and requires multiple daily doses to maintain elevated GHRH receptor stimulation. For recovery protocols, the DAC version is standard because it provides sustained pituitary priming without requiring multiple daily injections — the practical advantage outweighs any theoretical benefit of ultra-short pulsatile dosing.

Refrigerate both peptides at 2–8°C immediately after reconstitution. Use ipamorelin within 28 days, CJC-1295 with DAC within 60 days — the DAC modification provides greater stability. Any temperature excursion above 25°C for more than 4 hours causes irreversible protein denaturation that neither visual inspection nor home potency testing can detect. A vial accidentally left at room temperature overnight should be discarded regardless of appearance — denatured peptides produce zero biological effect but show no visible change.

Yes — the mechanisms are complementary rather than overlapping. CJC-1295 ipamorelin amplifies systemic GH/IGF-1 signaling that drives collagen synthesis and muscle fiber repair, while BPC-157 and TB-500 act through local anti-inflammatory and angiogenic pathways at the injury site. Clinical protocols for acute tendon or ligament injuries often stack all four peptides: CJC-1295 twice weekly, ipamorelin daily, BPC-157 and TB-500 injected locally near the injury site. This approach addresses both systemic anabolic signaling and localized tissue repair mechanisms simultaneously.

Most users report zero or minimal side effects at standard research doses. Transient water retention (mild peripheral edema) occurs in 10–15% of users during the first 2 weeks and typically resolves without intervention. Joint discomfort or carpal tunnel-like symptoms suggest excessive GH elevation — reduce ipamorelin dose by 25–50mcg. Persistent lethargy or training performance decline indicates mistimed dosing (likely suppressing natural nocturnal GH pulses) — shift administration to 30–60 minutes before bed. Serious adverse events are rare at doses below 300mcg ipamorelin and 200mcg CJC-1295.

Standard protocols run 8–12 weeks on followed by 4–8 weeks off to preserve receptor sensitivity and prevent hormonal adaptation. Continuous use beyond 12 weeks risks downregulation of ghrelin receptors and GHRH receptors, reducing the magnitude of GH pulses even with continued dosing. The off-cycle period allows receptor upregulation and restores natural pulsatility — users who skip the break typically report diminishing returns after week 10–12. For injury recovery, run the protocol through the acute healing phase (6–8 weeks), then discontinue; for chronic performance recovery, cycle 8 weeks on, 4 weeks off.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA